Trabodenoson

Drug Profile

Trabodenoson

Alternative Names: INO-8875; PJ-875

Latest Information Update: 07 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Inotek Pharmaceuticals
  • Class Antiarrhythmics
  • Mechanism of Action Adenosine A1 receptor agonists; Gelatinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Arrhythmias; Atrial fibrillation; Glaucoma; Ocular hypertension; Optic nerve disorders; Pain

Most Recent Events

  • 31 Jul 2017 Discontinued - Phase-III for Glaucoma in USA (Ophthalmic) ,
  • 31 Jul 2017 Discontinued - Phase-III for Ocular hypertension in USA (Ophthalmic) ,
  • 31 Jul 2017 Discontinued - Preclinical for Optic nerve disorders in USA (unspecified route) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top